| Robert A Wohlman, MD | |
|
1135 116th Ave Ne, Suite 560, Bellevue, WA 98004-4623 | |
| (425) 454-4768 | |
| (425) 462-8021 |
| Full Name | Robert A Wohlman |
|---|---|
| Gender | Male |
| Speciality | Gastroenterology |
| Experience | 43 Years |
| Location | 1135 116th Ave Ne, Bellevue, Washington |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1265412019 | NPI | - | NPPES |
| 1012699 | Medicaid | WA | |
| 13290 | Other | WA | L&I |
| Facility Name | Location | Facility Type |
|---|---|---|
| Virginia Mason Memorial | Yakima, WA | Hospital |
| Overlake Hospital Medical Center | Bellevue, WA | Hospital |
| Mercy Regional Medical Center | Durango, CO | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Washington Gastroenterology Pllc | 6204194848 | 115 |
| Yakima Valley Memorial Physicians | 1557391596 | 250 |
| Catholic Health Initiatives Colorado | 8022927342 | 998 |
News Archive
Researchers from Mount Sinai School of Medicine have identified a six-gene signature that can be used in a test to predict survival in men with aggressive prostate cancer, according to new research published in the October issue of The Lancet Oncology.
Blood diseases such as leukemia and lymphoma are currently treated with bone marrow transplants - a transfer of blood stem cells from a healthy person to a patient in need.
Only about one in four people diagnosed with acute myelogenous leukemia (AML) survive five years after the initial diagnosis.
Depomed, Inc. today announced that the New Drug Application (NDA) for DM-1796 was accepted by the U.S. Food and Drug Administration (FDA) for the management of postherpetic neuralgia (PHN), or pain after shingles. DM-1796 is an investigational, extended release, once-daily tablet formulation of gabapentin designed to reduce dosing frequency and have a low incidence of side effects.
According to a study presented November 4, 2009, at the 51st Annual Meeting of the American Society for Radiation Oncology (ASTRO), a shortened, more intensive course of radiation given to the whole breast, along with an extra dose of radiation given to the surgical bed of the tumor (concomitant boost), has been shown to result in excellent local control at a median follow up of two years after treatment with no significant sides effects.
› Verified 8 days ago
| Entity Name | Yakima Valley Memorial Physicians |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1306933940 PECOS PAC ID: 1557391596 Enrollment ID: O20050818000714 |
News Archive
Researchers from Mount Sinai School of Medicine have identified a six-gene signature that can be used in a test to predict survival in men with aggressive prostate cancer, according to new research published in the October issue of The Lancet Oncology.
Blood diseases such as leukemia and lymphoma are currently treated with bone marrow transplants - a transfer of blood stem cells from a healthy person to a patient in need.
Only about one in four people diagnosed with acute myelogenous leukemia (AML) survive five years after the initial diagnosis.
Depomed, Inc. today announced that the New Drug Application (NDA) for DM-1796 was accepted by the U.S. Food and Drug Administration (FDA) for the management of postherpetic neuralgia (PHN), or pain after shingles. DM-1796 is an investigational, extended release, once-daily tablet formulation of gabapentin designed to reduce dosing frequency and have a low incidence of side effects.
According to a study presented November 4, 2009, at the 51st Annual Meeting of the American Society for Radiation Oncology (ASTRO), a shortened, more intensive course of radiation given to the whole breast, along with an extra dose of radiation given to the surgical bed of the tumor (concomitant boost), has been shown to result in excellent local control at a median follow up of two years after treatment with no significant sides effects.
› Verified 8 days ago
| Entity Name | Washington Gastroenterology Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1306364401 PECOS PAC ID: 6204194848 Enrollment ID: O20180103000884 |
News Archive
Researchers from Mount Sinai School of Medicine have identified a six-gene signature that can be used in a test to predict survival in men with aggressive prostate cancer, according to new research published in the October issue of The Lancet Oncology.
Blood diseases such as leukemia and lymphoma are currently treated with bone marrow transplants - a transfer of blood stem cells from a healthy person to a patient in need.
Only about one in four people diagnosed with acute myelogenous leukemia (AML) survive five years after the initial diagnosis.
Depomed, Inc. today announced that the New Drug Application (NDA) for DM-1796 was accepted by the U.S. Food and Drug Administration (FDA) for the management of postherpetic neuralgia (PHN), or pain after shingles. DM-1796 is an investigational, extended release, once-daily tablet formulation of gabapentin designed to reduce dosing frequency and have a low incidence of side effects.
According to a study presented November 4, 2009, at the 51st Annual Meeting of the American Society for Radiation Oncology (ASTRO), a shortened, more intensive course of radiation given to the whole breast, along with an extra dose of radiation given to the surgical bed of the tumor (concomitant boost), has been shown to result in excellent local control at a median follow up of two years after treatment with no significant sides effects.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Robert A Wohlman, MD 1135 116th Ave Ne, Bellevue, WA 98004-4623 Ph: (425) 454-4768 | Robert A Wohlman, MD 1135 116th Ave Ne, Suite 560, Bellevue, WA 98004-4623 Ph: (425) 454-4768 |
News Archive
Researchers from Mount Sinai School of Medicine have identified a six-gene signature that can be used in a test to predict survival in men with aggressive prostate cancer, according to new research published in the October issue of The Lancet Oncology.
Blood diseases such as leukemia and lymphoma are currently treated with bone marrow transplants - a transfer of blood stem cells from a healthy person to a patient in need.
Only about one in four people diagnosed with acute myelogenous leukemia (AML) survive five years after the initial diagnosis.
Depomed, Inc. today announced that the New Drug Application (NDA) for DM-1796 was accepted by the U.S. Food and Drug Administration (FDA) for the management of postherpetic neuralgia (PHN), or pain after shingles. DM-1796 is an investigational, extended release, once-daily tablet formulation of gabapentin designed to reduce dosing frequency and have a low incidence of side effects.
According to a study presented November 4, 2009, at the 51st Annual Meeting of the American Society for Radiation Oncology (ASTRO), a shortened, more intensive course of radiation given to the whole breast, along with an extra dose of radiation given to the surgical bed of the tumor (concomitant boost), has been shown to result in excellent local control at a median follow up of two years after treatment with no significant sides effects.
› Verified 8 days ago
Joseph W Doucette, M.D. Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 1135 116th Ave Ne, Suite 600, Bellevue, WA 98004 Phone: 425-454-2656 Fax: 425-990-5261 | |
Roanne R E Selinger, MD Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 1135 116th Ave Ne, #560, Bellevue, WA 98004 Phone: 425-454-4768 Fax: 425-462-8021 | |
Patsy C Lazarous, MD Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 11511 Ne 10th St, Bellevue, WA 98004 Phone: 425-502-3000 Fax: 844-620-1839 | |
Dr. Patricia Martin, MD Gastroenterology Medicare: Not Enrolled in Medicare Practice Location: 1407 116th Ave Ne, Suite 200, Bellevue, WA 98004 Phone: 425-454-5046 Fax: 425-990-5261 | |
Dr. Rahil Barketali Roopani, M.D. Gastroenterology Medicare: Not Enrolled in Medicare Practice Location: 1800 116th Ave Ne Ste 102, Bellevue, WA 98004 Phone: 425-947-9485 Fax: 425-977-9034 | |
David C Morton, M.D. Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 1135 116th Ave Ne, Suite 110a, Bellevue, WA 98004 Phone: 425-289-3100 Fax: 425-289-3103 | |
Shie-pon Tzung, MD PHD Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 1135 116th Ave Ne, #560, Bellevue, WA 98004 Phone: 425-454-4768 Fax: 425-462-8021 |